Nipro Pharma to make generics in Vietnam
Earlier this week, Japan’s Nipro Corp announced that its subsidiary, Nipro Pharma, will set up a pharmaceutical plant in Vietnam.
The initial investment is estimated to be around 6 billion yen ($77.9 million), according to media reports. Initially, the new plant will engage in contract manufacturing of new drugs and generics focusing on injectables for developed markets such as Japan, Europe and the USA. Operations at the new plant are expected to commence around April 2015.
Last year, Sandoz, the generics subsidiary of Swiss drug major Novartis (NOVN: VX) entered into a strategic alliance with Nipro Corp, focussed on a broad range of cross-licensing and co-development opportunities for the Japanese generics market (The Pharma Letter July 14, 2011).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze